Expect to See Crizanlizumab or Voxelotor for Some Sickle Cell Patients

March 2020

Crizanlizumab (Adakveo, ah-DAK-vee-oh) and voxelotor (Oxbryta, oks-BRYE-tuh) will be new meds for sickle cell disease.

They may be added to hydroxyurea...the first-line option to reduce pain crises, hospitalizations, and possibly improve survival.

And they'll compete with oral L-glutamine (Endari)...which seems to reduce pain crises and possibly hospitalizations.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Transitions of Care Reduce Errors During Transitions to Outside Facilities
Infectious Diseases Assess if Dalbavancin or Oritavancin Can Expedite Discharges
Emergency Medicine Ensure Safe Use if Patients in the ED Need an Opioid
Infection Control Reinforce Infection Control in Light of Coronavirus
Vaccines Use Either Td or Tdap for Patients Needing a Tetanus Booster
New Drugs Skip New Acute Migraine Meds Ubrogepant and Lasmiditan
Hypertension Resist Adding PRN Meds for Severe Asymptomatic Hypertension
Sickle Cell Disease Expect to See Crizanlizumab or Voxelotor for Some Sickle Cell Patients
Osteoarthritis Update Your Osteoarthritis Treatment Strategies